Life Science Investing CytomX Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update
Life Science Investing CytomX Therapeutics to Present CX-801 Phase 1 Monotherapy Biomarker Data at the Society for Immunotherapy of Cancer Annual Meeting
Life Science Investing CytomX Therapeutics to Report Third Quarter 2025 Financial Results on November 6, 2025
Freegold Ventures Limited Announces Upsized Brokered Private Placement Financing from $30 Million to Up to $50 Million
